Adherence Assessments and the Use of Depot Antipsychotics in Patients With Schizophrenia

Valenstein, Marcia; Copeland, Laurel A.; Owen, Richard; Blow, Frederic C.; Visnic, Stephanie

doi:10.4088/jcp.v62n07a08

Cited by 92 publications

(63 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Depot antipsychotic medication is commonly prescribed in cases of poor adherence, particularly when covert non-adherence is suspected (Valenstein et al, 2001). Administration of a depot ensures either that a patient receives adequate levels of medication or that their failure to receive medication is detected early (through refusal or failure to attend for depot administration).…”

Section: Discussionmentioning

confidence: 99%

Insight and treatment attitude in schizophrenia: comparison of patients on depot and atypical antipsychotics

Mahadun¹,

Marshall

2008

Psychiatr. bull.

View full text Add to dashboard Cite

Aims and MethodTo establish if participants with schizophrenia receiving depot antipsychotics had less insight than similar participants receiving oral atypical antipsychotics. We assessed the difference between these two groups.ResultsParticipants on oral antipsychotics had greater insight than those on depot antipsychotics (ITAQ, P=0.01). In the multiple regression analysis, only receiving depot antipsychotics contributed significantly to explaining variance in insight (adjusted R2=0.135, F=8.99, P=0.004).Clinical ImplicationsDepot antipsychotics seem to be prescribed to a subgroup of people with schizophrenia who are likely to be less adherent because of lower levels of insight. These individuals are on significantly higher doses of antipsychotic medication. Clinicians should review their patients on depot antipsychotics at regular intervals.

show abstract

Section: Discussionmentioning

confidence: 99%

Insight and treatment attitude in schizophrenia: comparison of patients on depot and atypical antipsychotics

Mahadun¹,

Marshall

2008

Psychiatr. bull.

View full text Add to dashboard Cite

show abstract

“…Further, it is not known how many clinicians feel that there is a stigma attached to depot medication and that they do indeed represent a more coercive form of treatment. As noted above, prescribing practices for depots vary, and in the USA it has been reported that White patients are less likely to receive depot medication than Black and Hispanic patients (Valenstein et al, 2001). This is either evidence of bias against people from minority ethnic groups or preferential treatment, depending on one's point of view.…”

Section: Stigmamentioning

confidence: 99%

Why aren't depot antipsychotics prescribed more often and what can be done about it?

Patel¹,

David²

2005

Adv. psychiatr. treat

105

View full text Add to dashboard Cite

show abstract

“…Patients with chronic health conditions, especially in mental health, are known to be poorly adherent to medication regimes [2,3]. Poor-adherence to antipsychotic medicines is a correctable factor resulting in undesirable patient outcomes [4,5].…”

Section: Introductionmentioning

confidence: 99%

Development of a Controlled Release System for Risperidone Using Polypyrrole: Mechanistic Studies

et al. 2010

View full text Add to dashboard Cite

Polypyrrole (PPY) film has been selected as a platform material for drug delivery due to its inherent conductivity, ease of preparation and apparent biocompatibility. PPY films were prepared containing the antipsychotic drug risperidone as a model compound. Drug release profiles could be altered by applying different electrical stimulation to these films. Atomic force microscopy was used to investigate changes in PPY film thickness when different stimuli were applied. The highest levels of drug release were observed when PPY was reduced; this was accompanied by expansion of the film. Technology such as this could be utilized for implantable drug delivery devices, where the dose could be adjusted by external signaling.

show abstract

Adherence Assessments and the Use of Depot Antipsychotics in Patients With Schizophrenia

Cited by 92 publications

References 0 publications

Insight and treatment attitude in schizophrenia: comparison of patients on depot and atypical antipsychotics

Insight and treatment attitude in schizophrenia: comparison of patients on depot and atypical antipsychotics

Why aren't depot antipsychotics prescribed more often and what can be done about it?

Development of a Controlled Release System for Risperidone Using Polypyrrole: Mechanistic Studies

Contact Info

Product

Resources

About